An overview of the toxicities of checkpoint inhibitors in older patients with cancer

被引：15

作者：

Alkharabsheh, Omar ^{[1
]}

Kannarkatt, Paul ^{[2
]}

Kannarkatt, Joseph ^{[1
]}

Karapetyan, Lilit ^{[3
]}

Laird-Fick, Heather S. ^{[3
]}

Al-Janadi, Anas ^{[1
]}

机构：

[1] Michigan State Univ, Dept Med, Div Hematol Oncol, E Lansing, MI 48824 USA

[2] Cooper Univ Hosp, Dept Med, Camden, NJ USA

[3] Michigan State Univ, Dept Med, E Lansing, MI 48824 USA

来源：

JOURNAL OF GERIATRIC ONCOLOGY | 2018年 / 9卷 / 05期

关键词：

Immune checkpoint inhibitors; Immune-related adverse events; Elderly cancer patients; CELL LUNG-CANCER; NIVOLUMAB PLUS IPILIMUMAB; OPEN-LABEL; CHEMOTHERAPY TOXICITY; ANTI-PD-1; ANTIBODY; 1ST-LINE TREATMENT; T-CELLS; MULTICENTER; DOCETAXEL; PEMBROLIZUMAB;

D O I：

10.1016/j.jgo.2018.02.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Checkpoint inhibitors offer an exciting new option for treatment of a wide variety of cancers. By binding to surface receptors or their associated ligands on T cells, this class of drugs enhances immune activation and response to cancer cells. In available studies, the drugs are well tolerated, although toxicity involving skin, gastrointestinal tract, liver, lungs, and endocrine organs has been observed. Unfortunately, few studies to date have included patients older than 70 years of age. Since aging has been linked to changes in immune function, there are theoretical concerns that this patient population might experience a different profile of adverse events. This article reviews the tolerability of checkpoint inhibitors in older patients with cancer in clinical practice. (C) 2018 Elsevier Ltd. All rights reserved.

引用

页码：451 / 458

页数：8

共 55 条

[1] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[3] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[4] Age-dependent changes in the expression of regulatory cell surface ligands in activated human T-cells [J].

Canaday, David H. ;

Parker, Karen E. ;

Aung, Htin ;

Chen, Hui Emily ;

Nunez-Medina, Dariana ;

Burant, Christopher J. .

BMC IMMUNOLOGY, 2013, 14

[5] Comorbidity and geriatric assessment for older patients with hematologic malignancies: A review of the evidence [J].

Extermann, M. ;

Wedding, U. .

JOURNAL OF GERIATRIC ONCOLOGY, 2012, 3 (01) :49-57

[6] Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score [J].

Extermann, Martine ;

Boler, Ivette ;

Reich, Richard R. ;

Lyman, Gary H. ;

Brown, Richard H. ;

DeFelice, Joseph ;

Levine, Richard M. ;

Lubiner, Eric T. ;

Reyes, Pablo ;

Schreiber, Frederic J., III ;

Balducci, Lodovico .

CANCER, 2012, 118 (13) :3377-3386

[7] Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial [J].

Fehrenbacher, Louis ;

Spira, Alexander ;

Ballinger, Marcus ;

Kowanetz, Marcin ;

Vansteenkiste, Johan ;

Mazieres, Julien ;

Park, Keunchil ;

Smith, David ;

Artal-Cortes, Angel ;

Lewanski, Conrad ;

Braiteh, Fadi ;

Waterkamp, Daniel ;

He, Pei ;

Zou, Wei ;

Chen, Daniel S. ;

Yi, Jing ;

Sandler, Alan ;

Rittmeyer, Achim .

LANCET, 2016, 387 (10030) :1837-1846

[8] Performance of Four Frailty Classifications in Older Patients With Cancer: Prospective Elderly Cancer Patients Cohort Study [J].

Ferrat, Emilie ;

Paillaud, Elena ;

Caillet, Philippe ;

Laurent, Marie ;

Tournigand, Christophe ;

Lagrange, Jean-Leon ;

Droz, Jean-Pierre ;

Balducci, Lodovico ;

Audureau, Etienne ;

Canoui-Poitrine, Florence ;

Bastuji-Garin, Sylvie .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07) :766-+

[9] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].

Ferris, R. L. ;

Blumenschein, G., Jr. ;

Fayette, J. ;

Guigay, J. ;

Colevas, A. D. ;

Licitra, L. ;

Harrington, K. ;

Kasper, S. ;

Vokes, E. E. ;

Even, C. ;

Worden, F. ;

Saba, N. F. ;

Iglesias Docampo, L. C. ;

Haddad, R. ;

Rordorf, T. ;

Kiyota, N. ;

Tahara, M. ;

Monga, M. ;

Lynch, M. ;

Geese, W. J. ;

Kopit, J. ;

Shaw, J. W. ;

Gillison, M. L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867

[10] Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation [J].

Freeman, GJ ;

Long, AJ ;

Iwai, Y ;

Bourque, K ;

Chernova, T ;

Nishimura, H ;

Fitz, LJ ;

Malenkovich, N ;

Okazaki, T ;

Byrne, MC ;

Horton, HF ;

Fouser, L ;

Carter, L ;

Ling, V ;

Bowman, MR ;

Carreno, BM ;

Collins, M ;

Wood, CR ;

Honjo, T .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (07) :1027-1034

← 1 2 3 4 5 6 →